Private Equity Prescribes a Delisting for Recordati – Moby
THE GIST
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
A heavy-hitting buyout consortium led by private equity titan CVC Capital Partners and Belgium’s Groupe Bruxelles Lambert (GBL) has launched a €10.73 billion (about $12.47 billion) cash bid to take Italian pharmaceutical group Recordati private.
The voluntary tender offer aims to fully delist the 100-year-old company from Euronext Milan, allowing private equity players to pursue highly profitable rare-disease portfolios and dealmaking pipelines away from the short-term glare and volatility of public equity markets.
WHAT HAPPENED
The bid, formalized this Friday, settles months of speculation that began when CVC first lobbed a nonbinding expression of interest to Recordati’s board in March. The consortium is offering €51.29 in cash per share. When factoring in a €0.71 dividend that the Milan-listed laboratory paid out earlier this week, the total economic package values the transaction at an implied €52 per share.
The cash offer represents a 12.9% premium over Recordati’s share price on March 25, the final trading session before CVC’s initial overtures were made public. However, the price is slightly below Thursday’s closing price of €51.70 and falls short of the €60-plus price targets that some bullish equity analysts had assigned to the stock earlier this year. Shares in Milan nudged down marginally to trade at €51.55 on Friday, essentially anchoring themselves to the deal price.
The corporate layout for the acquisition is already structurally solid. CVC is not an outsider; it first invested in the company in 2018 by purchasing the founding family’s equity, and it currently holds a 46.8% stake through an investment vehicle called Rossini. Rossini has formally agreed to tender its entire block of shares into the new offer.
To cross the finish line and execute the squeeze-out, the consortium must secure at least 66.67% of Recordati’s total share capital. GBL is stepping up as a co-control partner, pledging to deploy up to 10% of its entire €13.3 billion investment portfolio to co-fund the deal. A roster of elite co-investors, including the Abu Dhabi Investment Authority, Canada’s CPP Investment Board, and current chairman Andrea Recordati, are also injecting cash to back the privatization.
WHY IT MATTERS
This is a defining moment for Europe’s corporate landscape, shaping up to be one of the largest healthcare buyouts the continent has witnessed in recent years.
Italy’s pharmaceutical industry is a crown jewel of its domestic manufacturing economy, boasting over 130 active production sites and a massive €21 billion trade surplus driven by surging global exports.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Recordati, which started in the 1920s as a local pharmacy in Correggio, grew into an industrial champion by churning out specialty care treatments for cardiovascular, urological, and gastrointestinal ailments.
But the real value engine for private equity is Recordati’s rapidly growing footprint in orphan and rare-disease treatments, such as metabolic and endocrine disorder therapies. The rare-disease segment is a highly lucrative, high-margin goldmine, but scaling it requires an aggressive, high-risk strategy of buying up entire specialist drug portfolios and absorbing early-stage biotech laboratories.
The consortium was remarkably candid about why they need to go dark to pull this off. In their joint statement, CVC and GBL argued that a private corporate structure gives Recordati an immediate cash cushion, completely shielding it from execution risks and the macroeconomic jitters gripping the public markets. With the ongoing war on Iran stoking global inflationary fears and whipping up broader market volatility, public shareholders are prone to panicking over erratic research and development cycles.
By pulling the plug on the Milan listing, the buyout specialists can operate with extended horizons. They do not have to explain to public asset managers why quarterly earnings dipped because they overpaid for a speculative biotech asset. Furthermore, the specialized nature of rare-disease drug distribution relies heavily on navigating complex direct-to-consumer and state-subsidized healthcare channels.
Private ownership allows the board to overhaul its commercial strategy without having to tip its hand to competitors through mandatory public disclosures.
WHAT’S NEXT
The consortium is aiming to finalize antitrust clearances and foreign direct investment approvals to close the deal in the fourth quarter of 2026. The key metric to watch over the coming weeks will be the compliance rate of the remaining institutional shareholders.
With block-builders like Fidelity Investments and Invesco each controlling 5% positions, and the Vanguard Group holding another 2.5%, Orcel-style holdout drama is always a background risk if funds decide to fight for a higher premium closer to that €60 mark. However, because the main holding vehicle Rossini is already locked in, the path toward hitting that 66.67% threshold looks highly achievable.
If the deal crosses the finish line by winter, it will signal that mega-cap private equity still has plenty of dry powder to rescue Europe’s elite mid-caps from the structural drag of public listings.
Leave a comment